| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Research Unit in Reproductive Medicine (A.L.-M., A.U.-A., P.M.C.), Instituto Mexicano del Seguro Social, México D.F. 10101, Mexico; Divisions of Neuroscience and Reproductive Biology (A.L.-M., J.A.J., P.M.C., A.U.-A.), Oregon National Primate Research Center, Beaverton, Oregon 97006; and Department of Physiology and Pharmacology and Cell and Developmental Biology, Oregon Health and Science University (P.M.C.), Portland, Oregon 97239
Address all correspondence and requests for reprints to: P. Michael Conn, Oregon National Primate Research Center/Oregon Health and Science University, 5050 NW 185th Avenue, Beaverton, Oregon 97006. E-mail: connm{at}ohsu.edu; or Alfredo Leaños-Miranda, Research Unit in Reproductive Medicine, Instituto Mexicano del Seguro Social, Apdo. Postal 99065, Unidad Independencia, México D.F., C.P. 10101, México. E-mail: alfredo{at}intranet.com.mx.
We analyzed the function of mutant GnRH receptor (GnRHR) pairs associated with compound heterozygous patients showing complete or partial forms of hypogonadotropic hypogonadism. We did this to examine potential interactions between misfolded mutants that may influence net receptor function and response to pharmacological rescue. Nine pairs of GnRHR mutants and an unreported combination (L314X(stop)/R262Q) were studied. Coexpression of each pair of mutants in COS-7 cells resulted in an active predominant effect (Q106R/L266R, A171T/Q106R, T32I/C200Y, and R262Q/A129D mutant GnRHR pairs), an additive effect (R262Q/Q106R, N10K/Q106R, and R262Q/Y284C human GnRHR pairs), or a dominant-negative effect (L314X(stop)/Q106R, Q106R+S217R/R262Q, and L314X(stop)/R262Q GnRHRs). For all combinations, addition of the pharmacoperone IN3 increased both agonist binding and effector coupling. The IN3 response was unpredictable because responses could be either similar, higher, or lower, compared with that exhibited by the less affected mutant. The clinical phenotype in patients expressing complex heterozygous alleles appears to be dictated by both the contribution from each mutant and a dominant-negative effect similar to that reported for mutants and wild-type receptor. Depending on the genotype, partial or full restoration of receptor function in response to pharmacological chaperones may be achievable goals in patients bearing inactivating mutations in the GnRHR gene.
This article has been cited by other articles:
![]() |
K. M. Wannemacher, P. N. Yadav, and R. D. Howells A Select Set of Opioid Ligands Induce Up-Regulation by Promoting the Maturation and Stability of the Rat {kappa}-Opioid Receptor in Human Embryonic Kidney 293 Cells J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 614 - 625. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Conn, A. Ulloa-Aguirre, J. Ito, and J. A. Janovick G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo Pharmacol. Rev., September 1, 2007; 59(3): 225 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
P M. Conn, J. A. Janovick, S. P Brothers, and P. E Knollman 'Effective inefficiency': cellular control of protein trafficking as a mechanism of post-translational regulation. J. Endocrinol., July 1, 2006; 190(1): 13 - 16. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |